Last reviewed · How we verify
AMT-116
At a glance
| Generic name | AMT-116 |
|---|---|
| Sponsor | Multitude Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- AMT-116 in Patients With Advanced Solid Tumors (PHASE1)
- AMT-116 in Patients with Solid Tumors (PHASE1, PHASE2)
- Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |